Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29057686 | 0.81 | MEN1 (0.38) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL4435307 | 0.79 | LMNA (0.48) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL4991499 | 0.79 | SMN1; SMN2 (0.41) | MAPTTDP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL27775270 | 0.79 | HTR7 (0.41) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6870490 | 0.76 | LMNA (0.45) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL2712919 | 0.76 | LMNA (0.45) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL28272326 | 0.76 | LMNA (0.50) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL27682606 | 0.76 | LMNA (0.45) | MAPTTDP1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL21906494 | 0.76 | SIGMAR1 (0.45) | MAPTSMN1; SMN2KDM4ETSHRKMT2A | |
| SCHEMBL27934059 | 0.76 | LMNA (0.45) | MAPTTDP1SMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058844-A1 | Process for producing retinol and intermediate compounds for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-16 | — | — | US | claimed |
| CN-106588818-B | Fluoro- 3- morpholinyl phenyl methylamine of a kind of medicine intermediate 2,6- bis- and preparation method thereof | 兰州大学 | 2019-07-26 | — | — | CN | disclosed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-106588818-A | Medicine intermediate 2,6-difluoro-3-morpholinophenyl methylamine and preparation method thereof | 兰州大学 | 2017-04-26 | — | — | CN | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| EP-2021316-A1 | INHIBITORS OF POLO-LIKE KINASES | Abbott Laboratories (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1883402-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007140233-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| EP-1149094-B1 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | disclosed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| CN-1003855-B | Process for preparing 1, 3-disubstituted 2-oxindoles | 美国辉瑞有限公司 | 1989-04-12 | — | — | CN | disclosed |
| CN-85101795-A | With 1, the two 2-oxyindoles that replace of 3-prepare pain killer and antiphlogistic | — | 1987-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | MAPT 1109/4885TDP1 1856/4885SMN1; SMN2 4130/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | MAPT 4368/4885TDP1 2489/4885SMN1; SMN2 4290/4885 |
| US-20020058844-A1 | Process for producing retinol and intermediate compounds for producing the same | ADH4, ADH1B, ADH7 | MAPT 4822/4885TDP1 4492/4885SMN1; SMN2 2604/4885 |
| US-20080306054-A1 | Pharmaceutical Compounds | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 82/4885TDP1 1397/4885SMN1; SMN2 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.